Results 21 to 30 of about 675 (153)

Multifactorial Perspective for Greening Solid-Phase Peptide Synthesis: Rigid Polyacrylate Macroporous Resin in Combination with Green Solvents. [PDF]

ChemSusChem
A rigid, non‐swelling polyacrylate resin enables greener solid‐phase peptide synthesis by allowing various green solvents during the peptide synthesis and significantly reduced process mass intensity without compromising peptide synthesis efficiency/purity.
Noki S, Kumar A, Zhang C, Basso A, Serban S, Kou X, Li Y, Sharma A, de la Torre BG, Albericio F.   +9 more
europepmc   +2 more sources

Silica-Assisted Solid-Phase Peptide Synthesis (SiPPS). [PDF]

J Pept Sci
The use of a non‐swelling resin for solid‐phase peptide synthesis allows the reduction of solvent consumption by up to 50%. ABSTRACT Non‐swelling silica‐based resin was used for peptide synthesis. The strategy used is similar to that of solid‐phase peptide synthesis (SPPS), referred to as silica‐assisted solid‐phase peptide synthesis (SiPPS).
Nkwanyana N, Kumar A, Chakraborty A, Potvin S, Thibaut-Koumba G, Nardone B, Beland F, Sharma A, de la Torre BG, Albericio F.   +9 more
europepmc   +2 more sources

German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP). [PDF]

Photodermatol Photoimmunol Photomed
ABSTRACT Background Afamelanotide 16 mg (SCENESSE) is the first approved treatment for erythropoietic protoporphyria (EPP). EPP is a rare autosomal recessive inherited disorder of the haem biosynthesis pathway, where patients experience severe and debilitating acute phototoxicity. It affects at least one in 140,000 of the European population.
Homey B, Schelonke K, Schlegel CM, Bruch-Gerharz D, Weller K, Kiefer L, Stölzel U, Staubach-Renz P, Wegner J, Keller-Melchior R, Walker G, Bochno M, Bilbao P.   +12 more
europepmc   +2 more sources

Real-world assessment of the patient profile, clinical characteristics, treatment patterns, and outcomes associated with erythropoietic and X-linked protoporphyria. [PDF]

J Dermatol
Abstract Erythropoietic protoporphyria (EPP) and X‐linked protoporphyria (XLP) are rare genetic disorders. There are limited data regarding how these disorders are managed in real‐world settings. The aim of this study was to document the characteristics and treatment patterns among patients diagnosed with EPP or XLP in general real‐world settings in ...
Silver SM, Houghton K, Hitchens A, Ansquer VD, Ciepielewska M.   +4 more
europepmc   +2 more sources

Vitiligo. [PDF]

J Dtsch Dermatol Ges
Summary Vitiligo is a common pigment disorder of the skin resulting in destruction of melanocytes. Non‐segmental vitiligo (NSV) is an autoimmune disorder. The etiopathogenesis of segmental vitiligo (SV) remains incompletely understood. Genetic predisposition and increased vulnerability of melanocytes towards stressors lead to a melanocyte‐specific CD8+
Böhm M, Tanew A.
europepmc   +3 more sources

An overview of benefits and risks of chronic melanocortin-1 receptor activation. [PDF]

J Eur Acad Dermatol Venereol
Thinner line widths indicate typical physiologic signalling, thicker lines indicate increased signalling and red x's indicate suppressed signalling. Larger eumelanin and pheomelanin ovals indicate higher protein synthesis, while smaller ovals indicate lower protein synthesis.
Böhm M, Robert C, Malhotra S, Clément K, Farooqi S.   +4 more
europepmc   +2 more sources

Characteristics of childhood vitiligo and the progress of its treatment

Pifu-xingbing zhenliaoxue zazhi, 2022
Vitiligo is a common depigmentation disease. Childhood vitiligo exhibits some characteristics in epidemiology, clinical manifestations, comorbidities, etc.
Xiuzhen LI, Xiulian XU
doaj   +1 more source

Recognized and Emerging Features of Erythropoietic and X-Linked Protoporphyria [PDF]

, 2022
Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are inherited disorders resulting from defects in two different enzymes of the heme biosynthetic pathway, i.e., ferrochelatase (FECH) and delta-aminolevulinic acid synthase-2 (ALAS2),
Andrea Ricci, Elena Di Pierro, Francesca Granata, Giacomo De Luca, Giovanna Graziadei, Luca Barbieri, Luisa Sarno, Mariateresa Rossi, Matteo Marcacci, Michele De Canio, Paolo Ventura   +10 more
core   +1 more source

Erythropoietic protoporphyria and afamelanotide: a patient’s perspective

Clinical and Experimental Dermatology, 2023
The patient explores the profound impact of erythropoietic protoporphyria (EPP) on her life to date. The clinician’s comment reviews the symptoms and diagnostic criteria for EPP, as well as the novel treatment afamelanotide for EPP.
O'Reilly, Marese, McGuire, Vicky A., Dawe, Robert S.   +2 more
openaire   +3 more sources

2019 FDA TIDES (Peptides and Oligonucleotides) Harvest

Pharmaceuticals, 2020
2019 has been an excellent year in terms of peptides and oligonucleotides (TIDES) approved by the FDA. Despite the drop in the number of total drugs approved by the FDA in 2019 in comparison with 2018 (48 vs.
Danah Al Shaer, Othman Al Musaimi, Fernando Albericio, Beatriz G. de la Torre   +3 more
doaj   +1 more source